MU-D201 / Medpacto - LARVOL DELTA

MedPacto’s oncology pipeline for blood cancer wins EU patent (Korea Biomedical Review) - "MedPacto said...that it has obtained a European patent for a pharmaceutical composition to prevent and treat blood cancer...The company plans to apply the patent to the development of MU-D201, a follow-up pipeline of new anticancer drug Vactosertib...MedPacto confirmed that MU-D201 inhibits DRAK2 and suppresses growth and metastasis of cancer and has an anticancer effect in a preclinical study....MedPacto won the same patent rights in several countries, including Korea, Japan and the U.S., before the commercialization of MU-D201."

Patent • Preclinical • Oncology